Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2009 Jul;192(1):18-23.
doi: 10.1016/j.cancergencyto.2009.02.017.

del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia

C Cameron Yin  1 , Lynne V Abruzzo, Xiaoyan Qiu, Effrosyni Apostolidou, Jorge E Cortes, L Jeffrey Medeiros, Gary Lu
Affiliations
Case Reports

del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia

C Cameron Yin et al. Cancer Genet Cytogenet. 2009 Jul.

Abstract

The del(15q) chromosomal abnormality is known to occur in acute leukemias, but has rarely been described in chronic myelogenous leukemia (CML). Described here are five cases of CML associated with del(15q): four men and one woman. Bone marrow aspirate smears showed increased blasts in all cases at the time of del(15q) detection, in accelerated phase in two cases and myeloid blast phase in three. Conventional cytogenetic analysis showed t(9;22) and del(15q), as well as other inconsistent clonal abnormalities. All patients received imatinib mesylate; four received additional chemotherapy, and two had allogeneic stem cell transplantation (ASCT). Of the three patients who did not receive ASCT, one died, one was in persistent blast phase, and one was in clinical remission with molecular evidence of residual disease at 16, 6, and 34 months, respectively, after identification of the del(15q). Of the two patients who had ASCT, one died and one was in clinical remission with molecular evidence of disease at 15 and 64 months, respectively, after identification of the del(15q). These findings indicate that del(15q) is a recurrent cytogenetic abnormality that may be seen at initial presentation of advanced disease or may emerge during disease progression. Del(15q) appears to be associated with a poor prognosis in CML.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Case 4. The bone marrow aspirate smear reveals numerous medium to large blasts with prominent nucleoli and scant to moderate amount of cytoplasm (Wright-Giemsa, x1000).
Figure 2
Figure 2
A. Case 4. Conventional cytogenetic analysis demonstrates 46,XX,t(9;22)(q34;q11.2),del(15)(q21),add(19)(p13). B. Composite karyotype (G-banding) showing the t(9;22)(q34;q11.2) and the del(15q), as well as the other random abnormalities for all the five cases as listed in Table II.
Figure 2
Figure 2
A. Case 4. Conventional cytogenetic analysis demonstrates 46,XX,t(9;22)(q34;q11.2),del(15)(q21),add(19)(p13). B. Composite karyotype (G-banding) showing the t(9;22)(q34;q11.2) and the del(15q), as well as the other random abnormalities for all the five cases as listed in Table II.
See this image and copyright information in PMC

References

    1. Rowley J. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;43:290–3. - PubMed
    1. Deininger M, Goldman JM. Chronic myeloid leukemia. Curr Opin Hematol. 1998;5:302–8. - PubMed
    1. Sawyers CL. Chronic myeloid leukemia. New Engl J Med. 1999;340:1330–40. - PubMed
    1. Sawyers CL. Signal transduction pathways involved in BCR/ABL transformation. Bailliere’s Clin Haematol. 1997;10:223–31. - PubMed
    1. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. New Engl J Med. 1999;341:164–72. - PubMed

Publication types